321 related articles for article (PubMed ID: 18985740)
41. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
42. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
[TBL] [Abstract][Full Text] [Related]
43. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
44. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
45. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M
J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030
[TBL] [Abstract][Full Text] [Related]
46. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
[TBL] [Abstract][Full Text] [Related]
47. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
Hesketh PJ; Grunberg SM; Herrstedt J; de Wit R; Gralla RJ; Carides AD; Taylor A; Evans JK; Horgan KJ
Support Care Cancer; 2006 Apr; 14(4):354-60. PubMed ID: 16450086
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
Osorio-Sanchez JA; Karapetis C; Koczwara B
Intern Med J; 2007 Apr; 37(4):247-50. PubMed ID: 17388865
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
50. [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Harousseau JL; Zittoun R; Bonneterre J; Hedouin M; Ouvry J
Bull Cancer; 2000 Jun; 87(6):491-7. PubMed ID: 10903790
[TBL] [Abstract][Full Text] [Related]
51. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
52. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
[TBL] [Abstract][Full Text] [Related]
53. Aprepitant for chemotherapy-induced nausea and vomiting.
Flemm LA
Clin J Oncol Nurs; 2004 Jun; 8(3):303-6. PubMed ID: 15208824
[TBL] [Abstract][Full Text] [Related]
54. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
55. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
Chan SL; Jen J; Burke T; Pellissier J
Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
[TBL] [Abstract][Full Text] [Related]
56. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.
Hu Z; Cheng Y; Zhang H; Zhou C; Han B; Zhang Y; Huang C; Chang J; Song X; Liang J; Liang H; Bai C; Yu S; Chen J; Wang J; Pan H; Chitkara DK; Hille DA; Zhang L
Support Care Cancer; 2014 Apr; 22(4):979-87. PubMed ID: 24276953
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Bodge M; Shillingburg A; Paul S; Biondo L
Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
[TBL] [Abstract][Full Text] [Related]
58. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
59. Aprepitant vs. multimodal prophylaxis in the prevention of nausea and vomiting following extended-release epidural morphine.
Hartrick CT; Tang YS; Hunstad D; Pappas J; Muir K; Pestano C; Silvasi D
Pain Pract; 2010; 10(3):245-8. PubMed ID: 20230453
[TBL] [Abstract][Full Text] [Related]
60. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]